Abstract

Objectives: This study aimed to evaluate the association between different body composition features with prognostic outcomes of intermediate stage hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).Methods: The areas and density of skeletal muscle area (SM) and adipose tissue [subcutaneous (SAT); visceral (VAT)] were calculated on the pre-TACE CT scans. Overall survival (OS) and progression-free survival (PFS) curves were calculated using the Kaplan–Meier method and compared with log-rank test. The discrimination and performance of body composition features were measured by area under time-dependent receiver operating characteristic (ROC) curve. Univariate and multivariate Cox proportional hazard analyses were applied to identify the association between body composition parameters and outcomes.Results: A significant prolonged OS and PFS was displayed by Kaplan–Meier curve analysis for HCC patients with VAT HU below −89.1 (25.1 months, 95% CI: 18.1–32.1 vs. 17.6 months, 95% CI: 16.3–18.8, p < 0.0001, 15.4 months, 95% CI: 10.6–20.2 vs. 6.6 months, 95% CI: 4.9–8.3, p < 0.0001, respectively). The 1-, 2-, 3-, and 5-year OS area under the curve (AUC) values of the VAT HU were higher than the other body composition parameters. Meanwhile, it is also found that 3-, 6-, 9-, and 12-month PFS AUC values of VAT HU were the highest among all the parameters. Univariate and multivariate Cox-regression analysis suggested a significant association between VAT density and outcomes (OS, HR: 1.015, 95% CI: 1.004–1.025, p = 0.005, PFS, HR: 1.026, 95% CI: 1.016–1.036, p < 0.0001, respectively).Conclusion: The VAT density could provide prognostic prediction value and may be helpful to stratify the intermediate stage HCC patients.

Highlights

  • MATERIALS AND METHODSTransarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate stage hepatocellular carcinoma (HCC) according to the widely applied Barcelona Clinic of Liver Cancer (BCLC) staging system (Marrero et al, 2018; Villanueva, 2019)

  • This study aimed to evaluate the association between different body composition features with prognostic outcomes of intermediate stage hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE)

  • A significant prolonged overall survival (OS) and progression-free survival (PFS) was displayed by Kaplan–Meier curve analysis for HCC patients with visceral adiposity tissue (VAT) Housfield units (HU) below −89.1 (25.1 months, 95% confidence interval (CI): 18.1–32.1 vs. 17.6 months, 95% CI: 16.3–18.8, p < 0.0001, 15.4 months, 95% CI: 10.6–20.2 vs. 6.6 months, 95% CI: 4.9–8.3, p < 0.0001, respectively)

Read more

Summary

Introduction

Transarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate stage hepatocellular carcinoma (HCC) according to the widely applied Barcelona Clinic of Liver Cancer (BCLC) staging system (Marrero et al, 2018; Villanueva, 2019). Considering that the predictive value of these parameters could not be validated in larger clinical trials, it is crucial that novel pre-treatment stratification strategies are corroborated in order to improve the overall survival (OS) for intermediate stage HCC patients. The correlation between sarcopenia and outcomes such as tumor response and survival in intermediate stage HCC patients undergoing TACE treatment has not been largely evaluated (Marasco et al, 2020). Mean tissue attenuation is measured on the computed tomography (CT) images, limit data are shown regarding the prognostic impact of tissue density in BCLC B stage HCC patients

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call